The global Non-Hormonal Contraceptives Market was valued at USD 19.9 billion in 2024 and is expected to grow at a CAGR of around 7.24% from 2025 to 2034. The market is experiencing strong growth as more consumers and healthcare providers seek contraceptive solutions that do not involve synthetic hormones, reducing concerns over side effects linked to hormonal methods such as mood changes or weight fluctuations. Products like condoms, copper IUDs, and other barrier devices offer effective pregnancy prevention while also providing protection against sexually transmitted diseases. Rising public awareness of safe sexual practices, growing preference for hormone-free birth control, and supportive government and NGO initiatives promoting family planning are further accelerating adoption globally. Additionally, increasing accessibility through retail and online distribution channels is enhancing market reach and consumer convenience.

The devices segment dominates the non-hormonal contraceptives market, with products such as condoms, intrauterine devices (IUDs), vaginal rings, and subdermal implants accounting for the largest share and projected to grow at a strong pace over the forecast period. Within this category, copper IUDs are widely preferred due to their long-acting, hormone-free protection, while condoms remain essential because of their accessibility and dual prevention of pregnancies and sexually transmitted diseases. The broad availability and ease of use of these devices support their position as the leading segment in the market.

The female segment dominates the non-hormonal contraceptives market, as women represent the primary users of long-acting reversible contraceptives such as copper IUDs, subdermal implants, and spermicidal products. Female contraceptive preferences are strongly influenced by factors like effectiveness, ease of use, and long-term protection, particularly for women nearing menopause who seek hassle-free solutions. This substantial demand from women drives the largest revenue share in the market.

The above 44 years age group dominates the non-hormonal contraceptives market, accounting for a majority share of revenue. Women in this age bracket often prefer long-term, hormone-free contraception due to health considerations and the desire to avoid unintended pregnancies as they approach menopause. The use of methods such as copper IUDs, vaginal creams, and permanent sterilization procedures contributes significantly to the segment’s lead.

The non-hormonal contraceptives market is evaluated across major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America, led by the U.S. and Canada, dominates the market due to high awareness of reproductive health, widespread adoption of condoms and copper IUDs, and strong presence of key manufacturers. Europe follows closely, with countries such as Germany, the UK, France, Spain, Italy, and the Netherlands benefiting from supportive government family planning programs and well-established healthcare systems. Asia Pacific is witnessing rapid growth across China, Japan, India, Australia, and South Korea, driven by large populations, high unmet contraceptive needs, and increasing awareness initiatives. Latin America and the Middle East & Africa are emerging markets, supported by improving access to contraception and expanding public health campaigns.

The Non-Hormonal Contraceptives Market is highly consolidated. Some of the market key players are AbbVie, Bayer, Church & Dwight Co., CooperCompanies, CUPID, FUJI LATEX, HLL Lifecare, Mankind, MAYER, Viatris, Okamoto, Pregna International, Reckitt, SMB, Veru